Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Ascending)
47335-0472-88 47335-0472 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 1, 2016 In Use
60429-0926-30 60429-0926 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 30, 2016 In Use
60505-2900-00 60505-2900 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2900-01 60505-2900 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2900-03 60505-2900 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2900-08 60505-2900 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2900-09 60505-2900 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2901-00 60505-2901 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2901-01 60505-2901 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2901-03 60505-2901 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2901-05 60505-2901 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60505-2901-09 60505-2901 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 5, 2016 In Use
60687-0192-21 60687-0192 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 15, 2016 In Use
00008-0100-01 00008-0100 Inotuzumab Ozogamicin Besponsa 0.25 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous Aug. 18, 2017 In Use
75987-0111-11 75987-0111 Interferon gamma-1b Actimmune 100.0 ug/.5mL Immunotherapy Cytokine Interferon Subcutaneous Dec. 1, 2013 In Use
00555-1054-56 00555-1054 Isotretinoin Claravis 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 9, 2003 In Use
00555-1054-86 00555-1054 Isotretinoin Claravis 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 9, 2003 In Use
00555-1055-56 00555-1055 Isotretinoin Claravis 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 9, 2003 In Use
00555-1055-86 00555-1055 Isotretinoin Claravis 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 9, 2003 In Use
00555-1056-86 00555-1056 Isotretinoin Claravis 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 18, 2006 In Use
00555-1057-56 00555-1057 Isotretinoin Claravis 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 9, 2003 In Use
00555-1057-86 00555-1057 Isotretinoin Claravis 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 9, 2003 In Use
10631-0115-31 10631-0115 Isotretinoin Absorica 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral June 8, 2012 In Use
10631-0116-31 10631-0116 Isotretinoin Absorica 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral June 8, 2012 In Use
10631-0117-31 10631-0117 Isotretinoin Absorica 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral June 8, 2012 In Use

Found 10,000 results in 4 milliseconds — Export these results